NCT02263547终止1 期
Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride
Derrick Scott Robertson1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2015年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Primary Outcome Measures: Teriflunomide Concentrations at Day 28
研究概览
简要总结
Primary Objective To determine if colestipol hydrochloride tablets can accelerate the elimination of teriflunomide. Teriflunomide will be administered for 14 days followed by colestipol dosing of 11 days. Total duration of the study is 40 days.
Secondary Objectives To collect information on the pattern of side effects with use of colestipol hydrochloride after teriflunomide administration and to determine the best duration of therapy needed for adequate elimination
详细描述
participants will be followed for 40 days to allow for time to administer a loading dose of teriflunomide and observe the elimination of that drug using colestipol hcl.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •To be eligible for entry into this study, candidates must meet all of the following eligibility criteria at the time of the baseline visit:
- •Participants having provided informed consent with signature on informed consent form: the informed consent process should be complete with full discussion of all requirements and possible risks.
- •Healthy volunteer*
- •Aged 18-45 years, inclusive
- •Body Mass Index of 18-29 kg/m2 (body weight of 40-85 kg for women and 50-95 kg for men) *Healthy volunteer is defined as free of concomitant medications and use of either treatment, as deemed by the Investigator, is not contraindicated with any past medical history of the participant.
排除标准
- •Current smoker or past history as smoker.
- •Unable to provide informed consent to participate in the study Such as a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study
- •Participant unlikely to comply with protocol as determined by Investigator, eg, uncooperative attitude, inability to return for follow-up visits
- •Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the participant at risk by participating in the study
- •Persistent significant or severe infection, either acute or chronic
- •Recent history of drug or alcohol abuse within that past 6 months (participants will be asked to refrain from alcohol and drug use during the course of the study)
- •Participant is the Investigator or any Sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof, directly involved in the conduct of the protocol
- •Prior use of any investigational drug in the preceding 6 months
- •Liver function impairment or persisting elevations (confirmed by retest) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or direct bilirubin greater than 2x the upper limit of normal range (ULN).
- •Pregnant or breast-feeding women or those who plan to become pregnant during the study
- •Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy.
- •Participants wishing to parent children (be a partner in the conception of a child) during the course of the trial.
- •Participants with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia (confirmed by retest):
- •Hematocrit < 35% and/or
- •Absolute white blood cell count < 3000 cells/mm3 (μL) and/or
- •Platelet count < 150 000 cells/mm3 (μL) and/or- Absolute neutrophil ≤ 1500 cells/mm3 (μL)
- •Any known history of severe preexisting constipation
- •History of swallowing disorder or difficulty swallowing
研究组 & 干预措施
teriflunomide elimination with colestipol
Other
干预措施: teriflunomide (Drug)
teriflunomide elimination with colestipol
Other
干预措施: Colestipol (Drug)
结局指标
主要结局
Primary Outcome Measures: Teriflunomide Concentrations at Day 28
时间窗: 28 days after the start in the study
After receiving 14 days of teriflunomide, participants will take 11 days of colestipol to wash out the teriflunomide (measuring the levels of teriflunomide in the blood at each visit)
次要结局
- Secondary Outcome Measure: Mean Percentage Change of Serum Teriflunomide Levels Percentage Change of Teriflunomide Concentrations at Day 8, Day 14, Day 26 ad Day 36 Following Administration of Colestipol Hydrochloride Tablets.(duration of study about 50 days)
研究者
Derrick Scott Robertson
Assistant Professor
University of South Florida
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World SettingOcular Surface DiseasePrimary Open Angle GlaucomaNCT04828057Santen Pharmaceutical (Taiwan) Co., LTD50
已完成
1 期
Study of Temsirolimus, Topotecan, and BortezomibAdvanced CancerNCT00770731M.D. Anderson Cancer Center80
进行中（未招募）
2 期
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord TransplantationHematologic MalignancyBone Marrow TransplantNCT04395222Weill Medical College of Cornell University21
终止
不适用
Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.RELAPSING REMITTING MULTIPLE SCLEROSISNCT02833714University of North Carolina, Chapel Hill26
招募中
2 期
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal CancerColorectal Cancer MetastaticChemotherapyTargeted TherapyImmunotherapyRadiotherapy, Intensity-ModulatedNCT06764680Sun Yat-sen University57